



Spyre Therapeutics, Inc. (f/k/a Aeglea BioTherapeutics, Inc.)  
CVR Payment Statement for Quarter Ending December 31, 2023

| <u>Line Item</u>                       | <u>Calculation Ref</u> | <u>Q4</u><br><u>Amount</u> |
|--|------------------------|----------------------------|
| Gross Proceeds                         | <b>A</b>               | \$ 1,839,970.00            |
| Permitted Deductions                   | <b>B</b>               | <u>29,269.66</u>           |
| Net Proceeds                           | <b>C = A + B</b>       | 1,869,239.66               |
| Adjustment Amount                      | <b>D</b>               | <u>-</u>                   |
| <b>CVR Cash Payment</b>                | <b>E = C + D</b>       | <b>1,869,239.66</b>        |
| Holdback, per CVR Payment definition   | <b>F = E x 15%</b>     | <u>(280,385.95)</u>        |
| <b>CVR Payment</b>                     | <b>G = E + F</b>       | <b>1,588,853.71</b>        |
| <br>                                   |                        |                            |
| <b>90% per Section 2.4</b>             | <b>H = G x 90%</b>     | <b>1,429,968.34</b>        |
| <br>                                   |                        |                            |
| <b>Number of Outstanding CVRs</b>      |                        | <b>94,280,501</b>          |
| <b>CVR Payment per Outstanding CVR</b> |                        | <b>\$ 0.015167</b>         |